Skip to main content
AnGes, Inc. logo

AnGes, Inc. — Investor Relations & Filings

Ticker · 4563 ISIN · JP3127700007 LEI · 529900HERUBGP6BTMO45 T Manufacturing
Open in API
Filings indexed 67 across all filing types
Latest filing 2026-03-25 Regulatory Filings
Country JP Japan
Listing T 4563

About AnGes, Inc.

https://www.anges.co.jp/en/

AnGes, Inc. is a biopharmaceutical company specializing in the research and development of gene-based and nucleotide-based medicines. The company's core focus is its Hepatocyte Growth Factor (HGF) gene therapy product, designed to treat ischemic diseases by regenerating blood vessels. This product was the first gene therapy medicine to receive marketing approval in Japan. AnGes leverages its expertise in plasmid DNA technology across its development pipeline, which also includes an NFkB decoy oligonucleotide and DNA vaccines. The company is dedicated to developing novel treatments for various conditions, including rare diseases.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 1% confidence The document is a statutory confirmation (“確認書”) submitted under the Financial Instruments and Exchange Act certifying the appropriateness of the company’s Securities Report for the 27th fiscal year. It is not the full annual report itself, nor an earnings release or other specialized item. It is therefore a general regulatory filing. Classification: RNS.
2026-03-25 Japanese
有価証券報告書－第27期(2025/01/01－2025/12/31)
Annual Report Classification · 1% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese equivalent of an Annual Report (10-K). It includes detailed financial statements, business indicators, and management information for the fiscal year ending December 31, 2025. It is not an announcement or a certification, but the full report itself. FY 2025
2026-03-25 Japanese
有価証券届出書（参照方式）
Share Issue/Capital Change Classification · 1% confidence The document is a '有価証券届出書' (Securities Registration Statement) filed with the Kanto Local Finance Bureau by AnGes, Inc. It details the issuance of new share acquisition rights (第46回新株予約権), including terms, pricing, and conditions for exercise. This type of regulatory filing for capital raising through the issuance of securities falls under the 'Share Issue/Capital Change' category.
2025-11-07 Japanese
確認書
Regulatory Filings Classification · 1% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification by the CEO of AnGes, Inc. regarding the accuracy of the interim report for the period ending June 30, 2025. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report type (like an interim report), should be classified as Regulatory Filings (RNS) rather than the report itself. H1 27
2025-08-13 Japanese
半期報告書－第27期(2025/01/01－2025/12/31)
Interim / Quarterly Report
2025-08-13 Japanese
臨時報告書
AGM Information Classification · 1% confidence The document is titled '臨時報告書' (Extraordinary Report) in the header and explicitly states in Section 1 ('提出理由') that it is being submitted based on regulations following the resolution of matters at the Annual General Meeting (定時株主総会) held on March 28, 2025. Section 2 details the resolutions passed, specifically the election of directors and auditors. This structure—reporting the results of a shareholder meeting—perfectly matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to the AGM, the content is the official voting outcome report, not the AGM presentation materials (AGM-R). The document length is short (2427 chars), but its content is a formal regulatory filing detailing vote counts, making DVA the most precise classification.
2025-03-31 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.